GlassScriptPhysician profile
Justin Lande
NPI 1538542378
$59,577.48
in general payments reported to CMS, 2019-2025
53 companies · $1,120 in 2025
The $1,120 reported for 2025 was more than what 86% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,272 · 2020: $14K · 2021: $21K · 2022: $17K · 2023: $2,221 · 2024: $1,988 · 2025: $1,120.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,330.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,329.50 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $48,273.98 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Eli Lilly and Company | $1,950.00 | 2022 | |
| Novo Nordisk INC | $1,510.20 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Abbvie INC. | $1,148.35 | 2021-2025 | |
| Glaxosmithkline, LLC. | $1,059.64 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Pfizer INC. | $560.76 | 2019-2025 | |
| Amgen INC. | $551.78 | 2019-2025 | Repatha, Otezla, Evenity |
| Astrazeneca Pharmaceuticals LP | $548.32 | 2019-2024 | Breztri, Farxiga, Airsupra |
| Novartis Pharmaceuticals Corporation | $469.02 | 2019-2025 | |
| Merck Sharp & Dohme LLC | $376.67 | 2019-2023 | Dificid, Zerbaxa |
| Boehringer Ingelheim Pharmaceuticals, INC. | $315.51 | 2019-2025 | Jardiance, Tradjenta, Synjardy |
| Otsuka America Pharmaceutical, INC. | $262.19 | 2022-2025 | Rexulti |
| Bayer Healthcare Pharmaceuticals INC. | $164.74 | 2022-2024 | |
| Sumitomo Pharma America, INC. | $164.73 | 2023-2025 | Gemtesa |
| Astellas Pharma US INC | $156.78 | 2019-2025 | Veozah, Myrbetriq |
Show all 53 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Justin Lande listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.